Table 2.
Association of the coefficient score with disease-specific survival in the study cohort and the validation cohort
| Patient groups | Subgroups | Tertile groups (cutoff points) | Study cohort | Validation cohort | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | Deaths (%) | HR (95% CI)a | p value of trend | N | Deaths (%) | HR (95% CI)a | p value of trend | |||
| All patients | Tertile 3 | 195 | 36 (18) | Ref. | 124 | 25 (20) | Ref. | |||
| Tertile 2 (− 4.32247) | 188 | 31 (16) | 1.31 (0.80–2.15) | 89 | 22 (25) | 1.66 (0.91–3.05) | ||||
| Tertile 1 (− 3.92950) | 185 | 69 (37) | 3.16 (2.08–4.80) | < 0.0001 | 95 | 35 (37) | 2.75 (1.56–4.85) | 0.0004 | ||
| Microsatellite instability | MSS | Tertile 3 | 175 | 35 (20) | Ref. | 114 | 25 (22) | Ref. | ||
| Tertile 2 (− 4.32247) | 161 | 29 (18) | 1.31 (0.79–2.17) | 79 | 21 (27) | 1.63 (0.88–3.01) | ||||
| Tertile 1 (− 3.92950) | 167 | 66 (40) | 3.11 (2.04–4.76) | < 0.0001 | 89 | 33 (37) | 2.65 (1.49–4.72) | 0.0009 | ||
| MSI-H | Tertile 3 | 20 | 1 (5) | Ref. | 10 | 0 (0) | Ref. | |||
| Tertile 2 (− 4.32247) | 27 | 2 (7) | NC | 10 | 1 (10) | NC | ||||
| Tertile 1 (− 3.92950) | 18 | 3 (17) | NC | NC | 6 | 2 (33) | NC | NC | ||
| BRAF mutation | Negative | Tertile 3 | 185 | 34 (18) | Ref. | 115 | 22 (19) | Ref. | ||
| Tertile 2 (− 4.32247) | 171 | 28 (16) | 1.23 (0.74–2.07) | 81 | 19 (23) | 1.53 (0.81–2.91) | ||||
| Tertile 1 (− 3.92950) | 166 | 61 (37) | 3.24 (2.09–5.02) | < 0.0001 | 93 | 34 (37) | 2.72 (1.53–4.85) | 0.0007 | ||
| Positive | Tertile 3 | 10 | 2 (20) | Ref. | 9 | 3 (33) | Ref. | |||
| Tertile 2 (− 4.32247) | 17 | 3 (18) | NC | 8 | 3 (38) | NC | ||||
| Tertile 1 (− 3.92950) | 19 | 8 (42) | NC | NC | 2 | 1 (50) | NC | NC | ||
| Tumor location | Proximal colon | Tertile 3 | 59 | 5 (8) | Ref. | 40 | 10 (25) | Ref. | ||
| Tertile 2 (− 4.32247) | 80 | 11 (14) | 2.60 (0.87–7.84) | 27 | 6 (22) | 0.99 (0.31–3.13) | ||||
| Tertile 1 (− 3.92950) | 71 | 25 (35) | 6.92 (2.46–19.4) | < 0.0001 | 41 | 14 (34) | 2.05 (0.79–5.34) | 0.1176 | ||
| Distal colon | Tertile 3 | 71 | 19 (27) | Ref. | 41 | 5 (12) | Ref. | |||
| Tertile 2 (− 4.32247) | 49 | 5 (10) | 0.73 (0.25–2.14) | 26 | 8 (31) | 1.76 (0.51–6.09) | ||||
| Tertile 1 (− 3.92950) | 56 | 20 (36) | 2.03 (1.05–3.94) | 0.0477 | 21 | 8 (38) | 6.00 (1.61–22.4) | 0.0098 | ||
| Rectum proximal | Tertile 3 | 65 | 12 (18) | Ref. | 43 | 10 (23) | Ref. | |||
| Tertile 2 (− 4.32247) | 59 | 15 (25) | 1.36 (0.62–3.01) | 36 | 8 (22) | 3.48 (0.97–12.4) | ||||
| Tertile 1 (− 3.92950) | 58 | 24 (41) | 3.59 (1.64–7.87) | 0.0012 | 33 | 13 (39) | 4.02 (1.38–11.7) | 0.0129 | ||
Abbreviations: CI confidence interval, HR hazard ratio, NC not calculated (< 5 patients)
aCox regression adjusted for age, sex, tumor stage, tumor location, chemotherapy, MSI status, and BRAF mutation status